Thyroid Is 1 of 11 Conditions Meta Names by Name

which eleven conditions does meta name in its health standard?

Meta's Health and Wellness advertising standard names eleven conditions by name: diabetes, herpes, autism, cancer, HIV, Alzheimer's, ALS, Parkinson's, psoriasis, ebola, and thyroid conditions, per the Meta Transparency Center. We counted the list straight off that live page rather than trust a secondhand summary — eleven, and no more.

Thyroid is the one this audience runs into constantly.

The other ten rarely touch a nutra media buyer's catalog. You will not often see an ebola offer or an ALS offer in a media plan, but diabetes and thyroid supplements are two of the most commonly run direct-response categories in this niche, which is exactly why this particular list is worth memorizing instead of skimming.

what specifically may an ad not claim about them?

Meta bars ads from claiming a product will cure, heal, or eliminate any of the eleven named conditions, and that bar holds even when the claim is attributed to a doctor or a health organization — Meta's rule allows symptom-management language but not a claim that the underlying condition goes away.

FDA's own enforcement record shows exactly the phrasing that trips this kind of wire in thyroid copy specifically. Its warning letter to Hekma Center, LLC quoted the company's own copy — "To balance thyroid gland functioning especially in case of Hypothyroidism" — as evidence the product was an unapproved drug. The hedge verb "balance" didn't neutralize the sentence, and it wouldn't neutralize a Meta review either.

Meta's separate rule on personal attributes closes the second-person version of the same move: an ad can't assert or imply that the viewer personally has the condition. "Your thyroid failing you?" reads as exactly the diagnosis-framing Meta's policy is built to catch, where a category reference — "thyroid support" — does not. If you're not sure which side of that line a given headline sits on, run the exact wording through a health claim checker before you spend a dollar on media rather than find out from a rejected ad account.

why does being named change the review outcome?

Named conditions get flagged categorically instead of judged case by case, which is the practical difference between this list and every other health claim Meta reviews. An unnamed symptom or a generic wellness claim gets evaluated on its own words; a claim touching diabetes, thyroid, or any of the other nine conditions gets matched against a fixed list first.

Being named also compounds risk beyond Meta. Thyroid dysfunction meets FDA's own definition of disease — "damage to an organ, part, structure, or system of the body such that it does not function properly" — on its face, and no FDA-authorized or qualified health claim for any thyroid outcome has ever existed. We checked FDA's list of nine qualified-claim categories and its twelve authorized health claims; thyroid appears in neither.

That double exposure is the reason a thyroid or diabetes offer deserves a different survival plan than a general supplement, and what specifically counts as an unapproved health claim under Meta's rules is the next thing worth reading before you build creative around either condition.

does the rule apply to the destination page and imagery too?

Yes. Meta states plainly that its ad review examines the ad's images, video, text, and targeting information, as well as "the ad's associated landing page or other destinations," and that ads can be reviewed again after they've already gone live.

FDA's enforcement record shows the same principle applied at scale. In its letter to ICA Health, LLC and Future Formulations, LLC, FDA cited an article on a separate, non-selling domain — "How Stress Affects the Body" — that never mentioned the product, then found that "you describe the products as treating stress or adrenal fatigue and on separate pages describe specific diseases as being linked to stress or adrenal fatigue" across the advertiser's whole web presence, aggregated across three properties.

The takeaway for a media buyer is that the safe headline on the ad does not protect a landing page that names the condition, and it does not protect an advertorial two clicks upstream of the offer either. That exposure carries forward into what audience restrictions Meta's health rules still leave open for retargeting, since the same funnel-wide review applies to whatever page a retargeted click lands on.

how do implied references to a named condition get treated?

Symptom clusters function as the named condition even when the word itself never appears on the page. FDA's rule reaches exactly this move under 21 CFR 101.93(g)(2)(ii): describing fatigue, cold hands and feet, hair thinning, unexplained weight gain, and brain fog together — presented as a recognizable cluster — is a lay-terminology symptom claim for hypothyroidism whether or not the word "thyroid" is printed anywhere.

We could not verify how precisely Meta's implied-claim doctrine mirrors that FDA standard. Meta's live Advertising Standards pages render client-side and returned no usable text on repeated attempts during our research, so the exact wording of its implied-reference rule for named conditions needs a direct read of the current policy page before you rely on it for a specific piece of creative.

What we can say with more confidence, from FDA's enforcement record, is that context decides the question rather than any single word. A symptom list built to be recognizable is functionally a diagnosis, and both regulators treat the whole page — not the isolated sentence — as the unit that gets judged.

which two of these conditions dominate nutra offers?

Diabetes and thyroid, by a wide margin, because they are the only two of the eleven with active direct-response supplement categories built around them — nobody is running a nutra funnel against ALS or ebola.

Enforcement volume tells you which one FDA watches harder, and it isn't close. On a single day, September 7, 2021, FDA's Center for Food Safety and Applied Nutrition issued ten coordinated warning letters to supplement sellers making diabetes claims, all charged as unapproved new drugs. Thyroid's warning-letter count is much thinner — 37 letters mentioning "thyroid" and only 10 mentioning "hypothyroidism," against 146 for "diabetes," as of the database we queried on August 7, 2026.

Most operators read that gap backwards. Low thyroid letter volume looks like room to move, and we'd argue it's the opposite — a thinner enforcement record reflects a smaller vertical, not a higher ceiling, and the ceiling itself is set by 21 CFR 101.93(g), which treats thyroid dysfunction as a disease with no carve-out at all, unlike weight loss's overweight-versus-obesity gap or menopause's hot-flash exception.

how should creative for a named condition be built differently?

Start by not naming the condition anywhere in the funnel — not in the headline, not in the brand name, not in the ingredient explainer, and not in the alt text on an image. Meta's rule and FDA's rule both read the whole property as one unit, so a compliant ad sitting in front of a page that names "thyroid" or "hypothyroidism" doesn't survive the review either regulator runs.

Second, treat a disclaimer as decoration, not defense. FTC's own guidance states that a disclaimer "directly contradictory" to an express claim is "ineffective to negate" it — the same logic Meta applies when it says a cure claim attributed to a health professional is still a cure claim.

Third, expect the funnel-level scrutiny to follow you into measurement, not just creative review. Advertisers in this category have also seen their conversion data get capped at the pixel level, so a thyroid or diabetes campaign built around lower-funnel optimization needs a plan for that restriction well before launch, not after the account gets flagged.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as Meta Ad Library, Meta advertising standards, and FTC health claims guidance. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Varicose Vein and Circulation Offers: Market and Claim Limits, Menopause and Women's Hormone Offers: Market and Rules, Fertility Offers: Two Buyers, High Emotion, and a Hard Claim Ceiling, Bladder and Pelvic Floor Offers: Market Map and Claim Limits, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.